Notably, ALK-G1269A, which is a secondary mutation found in a EML4-ALK-positive crizotinib-refractory NSCLC patients [36], together with the ALK-I1171N mutation, are more resistant to crizotinib. This evidence concerns the gene EML4 and non-small cell lung carcinoma.